DPYS Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- 产品详情
- 实验流程
- 背景知识
Application
| IHC-P, WB |
|---|---|
| Primary Accession | Q14117 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 56630 Da |
| Isotype | Rabbit IgG |
| Antigen Source | HUMAN |
| Gene ID | 1807 |
|---|---|
| Antigen Region | 454-482 aa |
| Other Names | Dihydropyrimidinase, DHP, DHPase, Dihydropyrimidine amidohydrolase, Hydantoinase, DPYS |
| Dilution | IHC-P~~1:100~500 WB~~1:1000 |
| Target/Specificity | This DPYS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 454-482 amino acids from the C-terminal region of human DPYS. |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | DPYS Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | DPYS |
|---|---|
| Function | Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate. |
| Tissue Location | Liver and kidney. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Dihydropyrimidinase catalyzes the conversion of 5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism. Dihydropyrimidinase is expressed at a high level in liver and kidney as a major 2.5-kb transcript and a minor 3.8-kb transcript. Defects in the DPYS gene are linked to dihydropyrimidinuria.
REFERENCES
Kim, H.Y., et al. BMB Rep 43(8):547-553(2010)
van Kuilenburg, A.B., et al. Biochim. Biophys. Acta 1802 (7-8), 639-648 (2010) :
Fidlerova, J., et al. Cancer Chemother. Pharmacol. 65(4):661-669(2010)
Thomas, H.R., et al. Pharmacogenet. Genomics 18(1):25-35(2008)
Thomas, H.R., et al. Pharmacogenet. Genomics 17(11):973-987(2007)
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。